Safety and Efficacy Results From Transcend NHL 001, a Multicenter Phase 1 Study of Lisocabtagene Maraleucel (Liso-Cel) In Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL)

被引：0

作者：

Abramson, Jeremy ^{[1
]}

Palomba, M. Lia ^{[2
]}

Gordon, Leo ^{[3
]}

Lunning, Matthew ^{[4
]}

Wang, Michael ^{[5
]}

Arnason, Jon ^{[6
]}

Mehta, Amitkumar ^{[7
]}

Purev, Enkhtsetseg ^{[8
]}

Maloney, David ^{[9
]}

Andreadis, Charalambos ^{[10
]}

Sehgal, Alison ^{[11
]}

Solomon, Scott ^{[12
]}

Ghosh, Nilanjan ^{[13
]}

Albertson, Tina ^{[14
]}

Garcia, Jacob ^{[14
]}

Kostic, Aria ^{[14
]}

Li, Daniel ^{[14
]}

Kim, Yeonhee ^{[14
]}

Siddiqi, Tanya ^{[15
]}

机构：

[1] Massachusetts Gen Hosp, Canc Ctr, Boston, MA 02114 USA

[2] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[3] Northwestern Univ, Feinberg Sch Med, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA

[4] Univ Nebraska Med Ctr, Omaha, NE USA

[5] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[6] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA

[7] Univ Alabama Birmingham, Birmingham, AL USA

[8] Univ Colorado, Sch Med, Aurora, CO USA

[9] Fred Hutchinson Canc Res Ctr, 1124 Columbia St, Seattle, WA 98104 USA

[10] Univ Calif San Francisco, San Francisco, CA 94143 USA

[11] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA

[12] Northside Hosp, Canc Inst, Immunotherapy Program, Atlanta, GA USA

[13] Atrium Hlth, Levine Canc Inst, Charlotte, NC USA

[14] Juno Therapeut, Seattle, WA USA

[15] City Hope Natl Med Ctr, 1500 E Duarte Rd, Duarte, CA 91010 USA

来源：

ONCOLOGY RESEARCH AND TREATMENT | 2020年 / 43卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

976

引用

页码：215 / 215

页数：1

共 50 条

[1] Safety and efficacy results from TRANSCEND NHL 001, a multicenter phase 1 study of lisocabtagene maraleucel (liso-cel) in relapsed/refractory large B-cell lymphoma
Abramson, J.
Palomba, M. L.
Gordon, L.
Lunning, M.
Wang, M.
Arnason, J.
Mehta, A.
Purev, E.
Maloney, D.
Andreadis, C.
Sehgal, A.
Solomon, S.
Ghosh, N.
Albertson, T.
Garcia, J.
Kostic, A.
Li, D.
Kim, Y.
Siddiqi, T.
BRITISH JOURNAL OF HAEMATOLOGY, 2020, 189 : 94 - 95
[2] Safety and Efficacy Results From Transcend NHL 001, a Multicenter Phase 1 Study of Lisocabtagene Maraleucel (Liso-cel) In Relapsed/refractory Large B-Cell Lymphoma
Abramson, Jeremy
Palomba, M. Lia
Gordon, Leo
Lunning, Matthew
Wang, Michael
Arnason, Jon
Mehta, Amitkumar
Purev, Enkhtsetseg
Maloney, David
Andreadis, Charalambos
Sehgal, Alison
Solomon, Scott
Ghosh, Nilanjan
Albertson, Tina
Garcia, Jacob
Kostic, Ana
Li, Daniel
Kim, Yeonhee
Siddiqi, Tanya
BONE MARROW TRANSPLANTATION, 2020, 55 (SUPPL 1) : 43 - 44
[3] Pivotal Safety and Efficacy Results from Transcend NHL 001, a Multicenter Phase 1 Study of Lisocabtagene Maraleucel (liso-cel) in Relapsed/Refractory ( R/R) Large B Cell Lymphomas
Abramson, Jeremy S.
Palomba, Maria Lia
Gordon, Leo I.
Lunning, Matthew A.
Wang, Michael L.
Arnason, Jon E.
Mehta, Amitkumar
Purev, Enkhtsetseg
Maloney, David G.
Andreadis, Charalambos
Sehgal, Alison R.
Solomon, Scott R.
Ghosh, Nilanjan
Albertson, Tina
Garcia, Jacob
Kostic, Ana
Li, Daniel
Kim, Yeonhee
Siddiqi, Tanya
BLOOD, 2019, 134
[4] Two-Year Follow-up of Transcend NHL 001, a Multicenter Phase 1 Study of Lisocabtagene Maraleucel (liso-cel) in Relapsed or Refractory (R/R) Large B-Cell Lymphomas (LBCL)
Abramson, Jeremy S.
Palomba, M. Lia
Gordon, Leo I.
Lunning, Matthew A.
Wang, Michael
Arnason, Jon E.
Purev, Enkhtsetseg
Maloney, David G.
Andreadis, Charalambos
Sehgal, Alison R.
Solomon, Scott R.
Ghosh, Nilanjan
Kostic, Ana
Kim, Yeonhee
Ogasawara, Ken
Dehner, Christine
Siddiqi, Tanya
BLOOD, 2021, 138
[5] Safety and Preliminary Efficacy in Patients With Relapsed/Refractory Mantle Cell Lymphoma Receiving Lisocabtagene Maraleucel (Liso-Cel) in TRANSCEND NHL 001
不详
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2019, 17 (08) : 8 - 9
[6] Safety and preliminary efficacy in patients (pts) with relapsed/refractory (R/R) mantle cell lymphoma (MCL) receiving lisocabtagene maraleucel (Liso-cel) in TRANSCEND NHL 001.
Wang, Michael
Gordon, Leo I.
Palomba, Maria Lia
Abramson, Jeremy S.
Andreadis, Charalambos
Ghosh, Nilanjan
Lunning, Matthew Alexander
Maloney, David G.
Farazi, Thalia Andrea
Garcia, Jacob
Xie, Benhuai
Newhall, Kathryn J.
Dehner, Christine
Siddiqi, Tanya
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[7] Characterization of cytokine release syndrome (CRS) and neurological events (NEs) in the phase I TRANSCEND NHL 001 trial of lisocabtagene maraleucel (liso-cel) for patients (pts) with relapsed/refractory (R/R) large B-cell lymphoma (LBCL).
Abramson, Jeremy S.
Siddiqi, Tanya
Gordon, Leo, I
Lunning, Matthew Alexander
Wang, Michael
Arnason, Jon E.
Mehta, Amitkumar N.
Purev, Enkhee
Maloney, David G.
Andreadis, Charalambos
Sehgal, Alison R.
Solomon, Scott R.
Ghosh, Nilanjan
Albertson, Tina M.
Garcia, Jacob
Kostic, Ana
Li, Daniel
Kim, Yeonhee
Palomba, Maria Lia
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[8] Lisocabtagene maraleucel (liso-cel) treatment of patients (pts) with relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma (NHL) and secondary CNS lymphoma: Initial results from TRANSCEND NHL 001.
Abramson, Jeremy S.
Palomba, Maria Lia
Arnason, Jon E.
Lunning, Matthew Alexander
Solomon, Scott R.
Farazi, Thalia
Garcia, Jacob
Xie, Benhuai
Newhall, Kathryn J.
Dehner, Christine
Siddiqi, Tanya
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[9] Pivotal Safety and Efficacy Results From TRANSCEND NHL 001, a Multicenter Phase 1 Study of Lisocabtagene Maraleucel in Relapsed/Refractory Large B-Cell Lymphomas
不详
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2020, 18 (02) : 8 - 10
[10] TRANSCEND FL: phase 2 study results of lisocabtagene maraleucel (liso-cel) in patients (pts) with relapsed/refractory (R/R) follicular lymphoma (FL)
Borchmann, Peter
Morschhauser, Franck
Dahiya, Saurabh
Palomba, M. Lia
Garcia-Sancho, Alejandro Martin
Reguera Ortega, Juan Luis
Kuruvilla, John
Jaeger, Ulrich
Cartron, Guillaume
Izutsu, Koji
Dreyling, Martin
Kahl, Brad
Ghesquieres, Herve
Ardeshna, Kirit
Goto, Hideki
Barbui, Anna Maria
Abramson, Jeremy S.
Fleury, Isabelle
Mielke, Stephan
Farazi, Thalia
Fasan, Omotayo
Lymp, James
Vedal, Min
Nishii, Rina
Avilion, Ariel
Papuga, Jessica
Nastoupil, Loretta J.
ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 : 142 - 143

← 1 2 3 4 5 →